Australia's most trusted
source of pharma news
Saturday, 17 May 2025
Posted 15 May 2025 AM
ASX-listed Mayne Pharma has received a cease and desist letter from the FDA over marketing materials for its oral contraceptive Nextstellis.
The letter, dated 28 April 2025, refers to a speaker deck used while marketing Nextstellis to healthcare professionals. It was sent by the Office of Prescription Drug Promotion (OPDP) of the FDA and comes as Mayne is in the process of being acquired.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.